Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 2, 1999, Pages 735-741

  Catella Lawson, Francesca ^c   Mcadam, Brendan ^c,f   Morrison, Briggs W ^d   Kapoor, Shiv ^a   Kujubu, Dean ^b   Antes, Lisa ^b   Lasseter, Kenneth C ^e   Quan, Hui ^d   Gertz, Barry J ^d   Fitzgerald, Garret A ^c  

^a General Clinical Research Center   (United States)

^b Division of Nephrology   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Clinical Pharmacology Associates Miami   (United States)

^f VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; INDOMETACIN; PROSTAGLANDIN DERIVATIVE; ROFECOXIB; THROMBOXANE; VASOACTIVE AGENT;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; NEPHROTOXICITY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM BALANCE; SODIUM EXCRETION; SODIUM RETENTION; URINARY EXCRETION;

6-KETOPROSTAGLANDIN F1 ALPHA; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; EICOSANOIDS; FEMALE; GLOMERULAR FILTRATION RATE; HEMODYNAMIC PROCESSES; HUMANS; INDOMETHACIN; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SODIUM; SULFONES; THROMBOXANE B2; WATER-ELECTROLYTE BALANCE;

EID: 0032948948     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. Barry OP, Pratico D, Lawson JA and FitzGerald GA (1997) Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 99:2118-2127.
2. Belch JJ, Capell HA, Cooke, ED, Kirby JD, Lau CS, Madhok R, Murphy E and Steinberg M (1995) Oral iloprost as a treatment for Raynaud's syndrome: A double blind multicentre placebo controlled study. Ann Rheum Dis 54:197-200.
3. Bernard GR, Reines HD, Halushka PV, Higgins SB, Metz CA, Swindell BB, Wright PE, Watts FL and Vrbanac JJ (1991) Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Am Rev Respir Dis 144:1095-1101.
4. Brash AR, Jackson EK, Saggese C, Lawson J, Oates JA and FitzGerald GA (1983) The metabolic disposition of prostacyclin in man. J Pharmacol Exp Ther 266:78-87.
5. 2 metabolites in humans. Thromb Res 47:647-656.
6. Catella F and FitzGerald GA (1990) Measurement of thromboxane metabolites by gas chromatography-mass spectrometry. Methods Enzymol 187:42-50.
7. 2: An index of thromboxane formation in the human circulation. Proc Natl Acad Sci USA 83:5861-5865.
8. Catella F, Johnson JM and FitzGerald GA (1989) Quantitative analysis of eicosanoids by gas chromatography-mass spectrometry, in Prostanoids and Drugs (Samuelsson B, Berti F, Folco G and Velo GP eds) pp 15-22, Plenum Press, New York.
9. Catella F, Nowak J and FitzGerald GA (1986b) Measurement of renal and nonrenal eicosanoid synthesis. Am J Med 81 (Suppl 2B):23-29.
10. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA and Trzaskos JM (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature (Lond) 378:406-409.
11. Ehrich E, Dallob A, Van-Heckea A, Depre M, Depeleire I, Brideau C, Hilliard D, Tanaka W, Mukhopadhyay S, Seibold J, Deshepper P and Gertz B (1996b) Demonstration of selective Cox-2 inhibition by MK 966 in humans. Arthritis Rheum 39:S81A.
12. Ehrich, E, Mehlisch D, Perkins S, Brown P, Wittreich J, Lipschutz K and Gertz B (1996a) Efficacy of MK-966, a highly selective inhibitor of Cox-2, in the treatment of postoperative dental pain. Arthritis Rheum 39:S81A.
13. Ehrich E, Schnitzer T, Kivitz A, Weaver A, Wolfe F, Morrison B, Zeng Q, Bolognese J and Seidenberg B (1997) MK-966, a highly selective Cox-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study. Arthritis Rheum 40:S85A.
14. Emery P (1996) Pharmacology, safety data and therapeutics of COX-2 inhibitors, in Improved Non-Steroidal Anti-Inflammatory Drugs (Vane J, Botting J and Botting R eds) pp 229-242, Kluwer, Dordrecht, the Netherlands.
15. Fitzgerald DJ, Catella F and FitzGerald GA (1986) Platelet activation in unstable coronary disease. N Engl J Med 315:983-989.
16. Fitzgerald DJ, Fragetta J and FitzGerald GA (1988) Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis J Clin Invest 82:1708-1713.
17. FitzGerald GA, Brash AR, Falardeau P and Oates JA (1981) Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 68:1272-1275.
18. FitzGerald GA, Friedman LA, Miyamori I, O'Grady J and Lewis PJ (1979) A double-blind placebo-controlled evaluation of prostacyclin in man. Life Sci 25:665-672.
19. 2 biosynthesis in cardiovascular disease. Circulation 67:1174-1177.
20. FitzGerald GA, Smith B, Pedersen AK and Brash AR (1984) Increased prostacyclin biosynthesis is increased in patients with severe atherosclerosis and platelet activation. N Engl J Med 310:1065-1068.
21. Guan Y, Chang M, Cho W, Zhang Y, Redha R, Davis L, Chang S, Dubois RN, Hao C and Breyer M (1997) Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 273:F18-F26.
22. Harris RC, McKanna JA, Akai Y, Jacobson HR and Dubois RN (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94:2504-2510.
23. Hla T and Neilson K (1992) Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89:7384-7388.
24. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA and Prescott SM (1993) Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 268:9049-9054.
25. Komhoff M, Grone HJ, Klein T, Seyberth HW and Nusing HW (1997) Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 272:F460-F468.
26. 2 using bonded-phase phenylboronic acid columns and capillary gas chromatography-negative ion chemical ionization mass spectrometry. Anal Biochem 150:463-470.
27. 2 in the human circulation. Anal Biochem 155:198-205.
28. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA and Smithies O (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473-482.
29. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S and Narumiya S (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (Lond) 388:678-682.
30. Murray MD and Brater DC (1993) Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 32:435-465.
31. Nies AS (1998) Renal effects of nonsteroidal anti-inflammatory drugs. Agents Actions Suppl 24:95-106.
32. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J and Patrono C (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271:1706-1712.
33. 2 production in healthy subjects. Thromb Res 17:317-327.
34. Reilly IAG and FitzGerald GA (1986) Eicosanoid biosynthesis and platelet function with advancing age. Thromb Res 41:545-554.
35. Smith WL, Garavito RM and DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2. J Biol Chem 271:33157-33160.
36. Topper JN, Cai J, Falb D and Gimbrone MA Jr (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93:10417-10422.
37. Wu KK (1997) Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis. Agents Actions Suppl 48:107-123.
38. Yang T, Singh I, Pham H, Sun D, Smart A, Schnermann JB and Briggs JP (1997) Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 274:F481-F489.
39. 2 production. J Pharmacol Exp Ther 283:1059-1075.